Skip to content

Clinical efficacy and safety of compound Unani formulation ( Gul-e-Dhawa, Gul-e-Pista, Gul-e-Fofil, Kahruba, Tabasheer, Kazmazij, Samagh-e-arabi) and Samar-e-Babool in management of Vulvovaginal candidiasis

Clinical efficacy and safety of compound Unani formulation Gul e Dhawa Gul e pista Gul e Fofil Kahruba Tabasheer Kazmazij Samagh e arabi and Samar e Babool in management of vulvovaginal candidiasis A randomized single blind controlled trial - Nil

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/05/111042
Enrollment
60
Registered
2026-05-26
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N72- Inflammatory disease of cervix uteri

Interventions

Intervention1: Gul e Dhawa Gul e pista Gul e Fofil Kahruba Tabasheer Kazmazij Samagh e arabi and Samar e Babool: Route : oral Dosage: 4 gram twice daily duration: 14 days in the form of powder and Sam

Sponsors

Rafia Nisar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Married patients in the age 18-50 years with complain of vulvovaginal pruritus, vaginal discharge, dysuria and dyspareunia, willing to take part and cooperate in the procedure. They also should not be participating in other clinical studies.

Exclusion criteria

Exclusion criteria: Unmarried, pregnant or lactating, woman, sexually transmitted infections, different from candidiasis, patients on oral contraceptive or using intrauterine contraceptive devices, patients with any systemic disorders like chronic renal failure, chronic lung disease, diabetes or cardiac dysfunction,patients who had received antifungal or antibiotics within previous two weeks, hyper sensitivity or allergy to antibiotics or any ingredient of trial product, genital malignancy, postmenopausal women, congenital mail formation and immune compromised patients

Design outcomes

Primary

MeasureTime frame
Improvement in clinical symptom to be assessed in both groups, namely, pruritus vulva (reduction in 5 D itch score) and curdy vaginal dischargeTimepoint: Improvement in clinical symptom to be assessed in both groups, namely, pruritus vulva (reduction in 5 D itch score) and curdy vaginal discharge

Secondary

MeasureTime frame
Improvement in wet mount microscopy (laboratory investigation) ,dyspareunea, and dysuria to be assessedTimepoint: 14 days

Countries

India

Contacts

Public ContactDr Fahmeeda Zeenat

Ajmal Khan Tibbiya College AMU Aligarh

fahmeedazeenat@gmail.com8149536134

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026